Thus, using senicapoc to block KCa3.1 channels, improved the locomotor function in a mouse model of PD [48] while a decrease in neuroinflammation and degradation of neuronal synapses were reported in AD mice [47]. Here, KCNN4 is linked to Alzheimer disease.